Introduction
Fgf21 is a hormonal factor that acts as a metabolic regulator and plays important roles in controlling glucose homeostasis, insulin sensitivity, and ketogenesis. 1, 2 Fgf21 is mainly produced and released into the blood by the liver, under the control of the transcription factor, peroxisome proliferator activated receptor-a (PPARa). 1, 3 Extra-hepatic tissues, such as white and brown adipose tissues (WAT and BAT, respectively) and skeletal muscle, also express Fgf21. [4] [5] [6] The action of Fgf21 on target cells requires FGF receptors (FGFRs) and b-klotho, which is a single-pass transmembrane protein that functions as an obligate cofactor for Fgf21 signaling. 7, 8 The endocrine actions of Fgf21 include: promoting glucose uptake by white adipocytes via induction of the glucose transporter, Glut1 9 ; activating brown fat thermogenic activity 10 ; and promoting the appearance of brown fat-like cells in white fat (the so-called "browning" process).
11 Fgf21 also has autocrine/paracrine effects, such as the ability to induce hepatic ketogenesis. 1 Recent studies have demonstrated that
Fgf21 plays an important role in cardiac remodeling. [12] [13] [14] [15] Notably, the heart is both a target and a source of Fgf21: cardiac tissues express FGFR1, b-klotho and Fgf21, 12 the latter of which protects the heart against pathologic cardiac hypertrophy and myocardial infarction in mouse models. 12, 13, 15 While these findings suggest that Fgf21 could have therapeutic potential, we do not yet fully understand the complete range of normal cardiac functions that involve Fgf21. A recent mouse study showed that the circulating levels of Fgf21 are increased in late pregnancy, and that the liver is the main contributor to these systemic levels. 16 However, we do not yet know the physiologic importance of this pregnancy-related upregulation of Fgf21 and/or its potential relevance to cardiac tissue. During pregnancy, the heart enlarges to compensate for the increased cardiac output; the increase in volume induces an eccentric hypertrophy characterized by chamber enlargement and a proportional change in wall thickness. 17 This cardiac remodeling is reversible and occurs without morbid effects on cardiac function, 18 but the underlying molecular mechanisms are not well known. 19 An improved understanding of the molecular mechanisms that specifically control this physiological hypertrophy in contrast with those in pathological hypertrophy could have important implications for the treatment of cardiac disease. During pregnancy, the hypertrophied heart exhibits increased fatty acid oxidation (FAO) and decreased glucose utilization. 20 In contrast, pathological cardiac hypertrophy is usually accompanied by a switch from fatty acid to glucose metabolism. As the heart is unable to maintain a constant contractile function when its energy comes from glucose instead of fatty acids, this is considered to be a cause (instead of a consequence) of the cardiac pathology. [21] [22] [23] [24] Here, we sought to determine the physiological role of Fgf21 during pregnancy, especially in relation to cardiac hypertrophy. We show that pregnancy increases systemic Fgf21 levels, cardiac Fgf21 expression, and Fgf21-mediated intracellular signaling in the heart. Moreover, we demonstrate that Fgf21 insufficiency (in Fgf21 -/-mice) blocks pregnancy-related physiological cardiac hypertrophy. These findings indicate that Fgf21 is a major mediator of cardiac hypertrophy during pregnancy.
Methods

Human samples
Plasma samples were obtained from pregnant women without gestational complications and with normal glycemic and insulin levels (n = 22, age = 33.1 ± 0.92) at week $30 of gestation. Age-matched plasma samples from non-pregnant women (n = 20, age = 33.77 ± 1.55) were used as controls. The study was approved by the Ethics Committee of Virgen de la Victoria Hospital and was conducted in accordance with the Declaration of Helsinki. All participants gave signed consent after being fully informed of the goals and characteristics of the study. Gnz /J) were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Wild-type (wt) littermates were used as controls for all experiments with Fgf21-null and PPARa-null mice. The wt, PPARa À/À , and Fgf21 À/À female mice were mated overnight. Age-matched non-pregnant (NP) female mice served as controls. NP and pregnant (P) mice at day 18 (d18) were killed by decapitation of sedated mice (isofluorane inhalation). Four-month-old female mice age-matched from wt and Fgf21 À/À mice were anesthetized with 1.5% isofluorane and subcutaneous Alzet osmotic minipumps containing PBS or isoproterenol (ISO), the latter calibrated to release the drug at a rate of 15 mg/kg/day for 7 days, were surgically implanted subcutaneously in the interscapular region of the mouse.
Animals
Female Wistar rats weighting 180-210 g were mated and on day 18 of gestation were killed by sedated decapitation (n = 5-6 animals per group, isofluorane inhalation).
All experiments were performed according to the guidelines from Directive 2010/63/EU of the European Parliament, and were approved by Institutional Animal Care and Use Committee of the University of Barcelona.
Echocardiography in pregnant mice
Mice were anesthetized with 1.5% isoflurane and cardiac dimensions were assessed by echocardiography using a commercially available system (Vivid Q; GE Healthcare, Piscataway, NJ, USA) equipped with a 12-MHz linear probe. Ventricular dimensions were measured using M-mode scans across the left ventricle.
Analysis of plasma metabolites and hormone levels
Glucose and triglyceride levels were measured using an Accutrend Technology system (Roche Diagnostics, Basel, Switzerland). Nonesterified fatty acids (NEFAs) and ketone bodies (KBs) were measured in serum using an in vitro enzymatic colorimetric assay (Wako Chemicals, Richmond, VA, USA). Leptin, insulin, resistin, interleukin-6 (IL-6), and plasminogen activator inhibitor-1 (PAI-1) were quantified in 20 lL of plasma using a multiplex system (MADPK-71K; Linco Research/ Millipore, Saint Charles, MO, USA) and a Luminex 100ISv2. Fgf21 plasma levels were measured using a mouse/human FGF21 ELISA kit (Biovendor, Modrice, Czech Republic).
Administration of Fgf21 in vivo
For analysis of acute signaling events in the heart, recombinant mouse Fgf21 (Phoenix Pharmaceuticals Inc., Burlingame, CA, USA) was administered to anesthetized adult mice via the inferior vena cava according to the previously reported method. 25 In brief, mice were anesthetized with 1.5% isoflurane inhalation, the peritoneal cavity was exposed, and either Fgf21 (50 ng/g) or saline was injected directly into the inferior vena cava in a total volume of 100 ml. After 10 min, the heart was dissected and frozen. Thereafter, it was stored at -80 C.
Heart histology
Each heart was extracted and cut transversely at mid-height. One half was fixed in 4% formaldehyde, embedded in paraffin, and sectioned. The sections were deparaffinized and stained with H&E for determination of cardiomyocyte size using the ImageJ software. Fibrosis was determined by Masson's trichrome staining (Panreac, Barcelona).
Gene expression
Total RNA was isolated from left ventricular tissues using TriPure (Roche, Indianapolis, IN, USA). RNA was extracted from the liver, BAT, and WAT using NucleoSpin RNA columns (Macherey-nagel GmbH & Co., Düren, Germany). RT was performed using random hexamer primers (Applied Biosystems, Foster City, CA, USA) and 0.5 lg RNA in total reaction volumes of 20 lL. TaqMan gene expression assays (Applied Biosystems) were used. The following reference genes were used: cyclophilin A for the heart, and the 18S rRNA for the liver, BAT, and WAT. and proteins were separated by 10% SDS-PAGE and transferred to Immobilon-P membranes (Millipore). Mitochondrial cytochrome c oxidase activity was measured using the Complex IV Activity Microplate Assay kit (Abcam) following the manufacturer's instructions.
FAO measurement
Oxidation of [14C]-oleic acid in freshly isolated heart homogenates was assessed as previously reported. 27 In brief, each tissue sample was homogenized in sucrose/Tris/EDTA buffer and incubated for 60 min in a reaction mixture (pH 8.0) containing [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C] oleic acid, and then trapped CO 2 was measured.
Statistical analysis
The results are presented as the mean ± SEM. Data were analyzed by Mann-Whitney U test or two-way ANOVA with Tukey's posthoc test, as appropriate. Analyses were performed using the GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA). A P-value of <0.05 was considered to be statistically significant.
Results
Systemic Fgf21 levels and hepatic and cardiac expression of Fgf21 are increased during pregnancy in a PPARa-dependent manner
To determine the role of Fgf21 during pregnancy, we analyzed the levels of circulating Fgf21 in non-pregnant and late pregnant mice, rats, and humans, and found that the plasmatic levels of Fgf21 significantly increased during pregnancy in all three species ( Figure 1A) . We then analyzed the expression levels of Fgf21 in the liver, WAT, BAT, and heart of non-pregnant and late pregnant mice (day 18), and observed inductions of the mRNA levels of Fgf21 in the heart and liver, but not in BAT or WAT ( Figure 1B) . The expression levels of Fgf21 in mouse placentae were only $1% of those observed in the liver, and in human placentae were undetectable (data not shown). To examine whether PPARa might contribute to controlling Fgf21 in this system, we assessed Fgf21 expression in PPARa-null mice (PPARa -/-mice). As shown in Figure 1C , the plasma, liver, and cardiac levels of Fgf21 were decreased in pregnant PPARa -/-mice compared with pregnant wt mice. This suggests that PPARa contributes to controlling cardiac Fgf21 expression during pregnancy. In order to rule out a potential effect of other PPAR isoforms which could be modified by the lack of PPARa, we analyzed the expression levels of the other members of the PPAR family. We did not observe any difference in the expression of PPARb or PPARc in the PPARa -/-mice compared with the wt mice during pregnancy in any of the tissues studied (see Supplementary material online, Figure S1 ). These results collectively indicate that the plasma protein levels, and the hepatic and cardiac expression levels of Fgf21 are increased during pregnancy, and that this enhancement is mediated via the transcription factor, PPARa.
FGFR1 and b-klotho are induced in late pregnancy
To begin characterizing Fgf21 signaling during pregnancy, we next analyzed the expression levels of Fgf21 receptor (FGFR) and its coreceptor, b-klotho. Interestingly, whereas the mRNA expression and protein levels of FGFR in the liver, WAT, and BAT were either not altered (in WAT and BAT) or tend to be reduced (in the liver) by pregnancy, the mRNA expression levels of cardiac FGFR1 were more than two-fold higher in pregnant mice than in non-pregnant mice ( Figure 2A) . Similarly, the mRNA and protein levels of b-klotho were unchanged in liver, WAT, and BAT, but dramatically up-regulated in the cardiac tissues of late pregnant mice versus non-pregnant mice (37-fold the mRNA expression levels and two-fold the protein levels) ( Figure 2B ). Thus, pregnancy appears to specifically induce FGFR1 and b-klotho in the heart.
Pregnancy activates Fgf21 signaling in the heart
To further determine the status of intracellular Fgf21 signaling during pregnancy, we analyzed the phosphorylation of extracellular signalregulated kinase-1/2 (ERK1/2), which is a known indicator for the b-klotho/FGF receptor-dependent cellular response to Fgf21, 28 in pregnant and non-pregnant mice 10 min after systemic injection of PBS (control) or Fgf21. As shown in Figure 3A , injection of Fgf21 to non-pregnant mice increased ERK1/2 phosphorylation in liver, WAT, and BAT whereas pregnant mice failed to show any change in ERK-1/2 phosphorylation in response to Fgf21. This suggests that pregnancy may trigger some extent of resistance to Fgf21 signaling in those tissues. However, the levels of ERK-1/2 phosphorylation were increased in the hearts of non-pregnant mice but also in the hearts (but not other tissues) of pregnant mice under basal conditions, and this enhancement was sustained following Fgf21 injection. As Fgf21 signaling via intracellular phosphorylation of ERK-1/2 is known to induce the genes Egr1 and cFos, 25 we also used the expression of these genes as readout for Fgf21 action after Fgf21 injection ( Figure 3B ). We found that only in the heart the expression levels of both Egr1 and cFos were significantly induced 10 min after Fgf21 injection both in non-pregnant and in pregnant mice thus indicating a preferential activation of the Fgf21 intracellular pathways in the heart in both nonpregnant and pregnant conditions. Therefore, pregnancy is associated with increased cardiac ERK-1/2 phosphorylation, and Fgf21 signaling appears to undergo sustained activation in the heart of pregnant mice in contrast to the other tissues that appear to be resistant to Fgf21 in pregnancy.
Cardiac gene expression downstream of Fgf21 signaling is induced during pregnancy
Next, we studied late pregnancy in Fgf21 À/À mice. As presented in Supplementary material online, Table S1 , pregnant wt and Fgf21 À/À mice exhibited similar increases in body weight relative to non-pregnant mice. There was no difference in the litter size or average fetal weight between pregnant wt and Fgf21 À/À mice. However, the fetal/placental weight ratio, an indicator of compromised perinatal outcome, [29] [30] [31] was reduced in Fgf21 À/À mice indicating some degree of altered pregnancy. As expected, pregnancy increased blood triglycerides (TGs), although this difference was only significant for the Fgf21 À/-pregnant mice. No significant difference between groups was found in the circulating glucose, NEFAs, KBs (ketone bodies), IL-6, insulin, or resistin levels. The levels of PAI-1 and leptin were significantly higher in pregnant mice, as previously described 32, 33 ; however, there was no additional difference in Fgf21
mice. Collectively, these results indicate that Fgf21 deficiency does not trigger any major alteration in the mother in terms of body weight or the metabolic profile during late gestation but some signs of compromised perinatal outcome associated with the lack of Fgf21 occur. Next, we analyzed Fgf21 signaling pathway in pregnant wt and Fgf21 À/À mice. As shown in Figure 4A , there was no significant difference in the expression levels of Egr1 or cFos in the liver, WAT, or BAT of wt and Fgf21 À/À pregnant mice. In contrast, Egr1 mRNA expression was dramatically increased in the hearts of pregnant wt mice, whereas this increase was abrogated in pregnant Fgf21 À/À mice. Similarly, the mRNA expression of cFos was strongly and specifically induced in the hearts of pregnant wt mice, whereas a much smaller increase was seen in pregnant Fgf21 À/À mice. Consistent with these findings, analysis of basal cardiac ERK-1/2 phosphorylation showed a significant reduction in ERK-1/2 phosphorylation in pregnant Fgf21 À/À mice relative to pregnant wt mice ( Figure 4B ). These data indicate that pregnancy is associated with activated ERK1/2 signaling pathway in the heart in an Fgf21-dependent manner.
Lack of Fgf21 impairs cardiac remodeling in late pregnancy
Based on the heart-specific changes in Fgf21 signaling during pregnancy, we postulated that this factor may be important for the physiological adaptation of the heart to pregnancy (i.e. hypertrophy). We therefore analyzed the impact of Fgf21 knockout on cardiac morphology at day 18 of gestation in wt and Fgf21 À/À mice. As shown in Figure 5A , the heart weight/tibia length (HW/TL) ratio, a measure of cardiac enlargement, was significantly increased in pregnant wt mice but not in pregnant Fgf21 À/À mice. Echocardiographic measurements ( of the cardiomyocytes at basal levels relative to wt mice. The area of cardiomyocytes was significantly higher in pregnant wt mice than in nonpregnant wt mice, whereas a slight decrease in this CSA was observed in pregnant Fgf21 À/À mice relative to non-pregnant Fgf21 À/À mice ( Figure 5B ). Next, in order to determine the role of Fgf21 in a physiological condition of cardiac hypertrophy such as pregnancy in comparison with pathological cardiac hypertrophy, we used isoproterenol infusion to induce pathological hypertrophy, as previously reported 34 (Supplementary material online, Table S2 ). Echocardiographic measurements showed that in basal conditions Fgf21 À/À mice already develop some degree of cardiac hypertrophy and dilatation, but in contrast with pregnancy, cardiac hypertrophy was significantly enhanced in Fgf21 À/À mice compared to wt mice after isoproterenol infusion. This data indicate a distinct role of Fgf21 in pathological-vs.-physiological stimuli of cardiac hypertrophy. Together, these results indicate that 18-day pregnant mice exhibit cardiac hypertrophy and chamber dilatation, as expected, but Fgf21 knockout suppresses this characteristic response to pregnancy.
Fgf21 mildly alters the pathological markers of cardiac hypertrophy and fibrosis in pregnancy
It has been shown that pregnancy-related cardiac hypertrophy does not induce markers of pathologic cardiac hypertrophy, such as atrial natriuretic factor (Anf) and a-actinin (a-Ska). 17 Indeed, we confirmed that the mRNA expression levels of Anf and a-Ska were not significantly different in the hearts of pregnant and non-pregnant wt mice ( Figure 5A ). Fibrosis, which develops in the heart under pathologic conditions, is considered to be a hallmark of pathologic cardiac hypertrophy but is not seen during pregnancy-induced cardiac hypertrophy. 35 Here, we used Masson's Trichrome staining and mRNA expression analysis of MMP9 (matrix metalloproteinase-9), Col3 (Collagen 3), and TGFb (Transforming growth factor beta) to assess fibrosis in the hearts of pregnant wt and Fgf21 À/À mice ( Figure 5C and D) . We observed a significant increase in the expression levels of Col3 and specially TGFb, the master regulator of fibrosis, in the hearts of Fgf21 À/À mice pregnant mice but we did not found evidences of overt fibrosis in the Masson's Trichrome staining. Based on these results, we conclude that the physiologic induction of cardiac hypertrophy during pregnancy is not associated with changes in cardiac fibrosis in wt mice but some signs of fibrosis enhancement occur in Fgf21 À/À mice. 
Fgf21 knockdown impairs pregnancyinduced promotion of cardiac FAO
Pregnancy is characterized by increased FAO in the heart. 20 To address the impact of Fgf21 knockdown on metabolic control during late gestation, we first evaluated the cardiac FAO rates in pregnant wt and Fgf21 À/À mice. As shown in Figure 6A , the cardiac FAO rate was significantly higher in pregnant wt mice compared with non-pregnant wt controls, but that in pregnant Fgf21 À/À mice was significantly lower than that in pregnant wt mice. These results indicate that the utilization of fatty acids is reduced in the hearts of Fgf21 knockout mice during pregnancy.
Next, we examined the mRNA expression levels of four genes that encode the FAO-related proteins: medium-chain acyl-CoA dehydrogenase (Mcad), pyruvate dehydrogenase kinase-4 (Pdk4), Cd36 (a fatty acid transporter), and carnitine palmitoyltransferase (cpt1b). As shown in Figure 6B , pregnancy tend to increase the cardiac expression levels of all these genes in wt mice and Fgf21 -/-mice, but only the increase of pdk4 was statistically significant in wt mice and it was significantly reduced in Fgf21 -/-mice. We also analyzed the expression levels of Glut1 (a constitutive glucose transporter) and Glut4 (an insulin-dependent glucose transporter). As shown in Figure 6B , pregnancy tended to decrease the mRNA expression of Glut1 in wt and Fgf21 À/À mice to a non-significant degree. Glut4, in contrast, was unchanged in pregnant wt mice, but was significantly increased in pregnant Fgf21 À/À mice. This suggests that the hearts of pregnant Fgf21 -/-mice may exhibit increased glucose uptake.
Next, we analyzed the PGC1a and mitochondrial OXPHOS protein levels (simultaneous measurement of five subunits of distinct respiratory chain/oxidative phosphorylation system) as well as we determined cytochrome c oxidase activity in the heart from our experimental settings ( Figure 6C and D and Supplementary material online, Figure S2 ). We found a significant reduction in the protein levels of cytochrome c oxidase subunits (II and IV) and a tendency to a lower cytochrome c oxidase activity specially when comparing hearts from Fgf21-null pregnant vs. non-pregnant mice ( Figure 6C and D) , indicating a mild impairment in overall mitochondrial oxidative activity due to the lack of Fgf21 during pregnancy. No major changes were observed either in the PGC1a protein levels or in the protein levels of the other subunits of the respiratory chain/oxidative phosphorylation system analyzed ( Figure 6D and Supplementary material online, Figure S2) .
Collectively, these data indicate that a lack of Fgf21 during pregnancy decreases the usage of fatty acids in the heart, potentially compromising cardiac function during pregnancy.
Discussion
This study shows that Fgf21 levels increase during pregnancy. In mice, this is associated with enhanced expression of Fgf21 in the liver but not in adipose tissues. Considering the high extent of Fgf21 expression in the liver relative to other tissues, the liver is likely to account for the pregnancy-related increase in Fgf21 levels. These results confirm a previous report by Cui et al. 16 Moreover, we report a similar upregulation of Fgf21 in healthy pregnant women relative to non-pregnant, non-lactating, women, in agreement with previous studies comparing pregnancy vs. post-partum Fgf21 levels. 36, 37 Previous studies also reported two-to three-fold higher circulating levels of Fgf21 in women suffering from gestational diabetes and preeclampsia near delivery, compared with women experiencing normal gestation. 36, 38 . The higher levels of Fgf21 during pathological conditions might indicate some phenomena of Fgf21 resistance as previously reported during obesity and diabetes. 25, 39, 40 The parallel reductions in the levels of circulating and hepatic Fgf21 in mice lacking PPARa, a master regulator of Fgf21 gene expression in liver, further supports the hepatic origin of the pregnancy-related upregulation of Fgf21. Moreover, the very low expression of Fgf21 in mouse and human placentae argue against a possible placental origin for the high-level expression of Fgf21 during pregnancy.
In contrast to almost all extra-hepatic tissues, we found that Fgf21 expression is strongly induced in the hearts of pregnant mice. Moreover, this upregulation is impaired in PPARa-null mice, indicating that PPARa plays a pivotal role in controlling cardiac Fgf21 expression during pregnancy. The contribution of the heart to systemic Fgf21 is not yet known, but a recent report found that cardiac-specific overexpression of Fgf21 in transgenic mice increased the circulating levels of Fgf21. 41 However, although some contribution cannot be ruled out, the relatively low magnitude of Fgf21 expression in the heart compared to that in the liver 12 makes it seem unlikely that the pregnancy-related upregulation of systemic Fgf21 could have a mainly cardiac origin. We herein show that, in addition to increased expression of Fgf21, the heart shows marked signs of enhanced Fgf21 action during pregnancy, including: major upregulation of b-klotho, which is a co-receptor required for the biological action of Fgf21; marked heart-specific activation of ERK1/2, which is the canonical intracellular pathway known to transduce the actions of Fgf21 and consistent with previous findings showing cardiac ERK1/2 phosphorylation during pregnancy 42, 43 ; and strong expression of the ERK-1/2-responsive genes, Egr1, and cFos. 8, 28 During pregnancy, therefore, the heart appears to be highly sensitive to and strongly targeted by Fgf21 of systemic and/or local origin.
We previously reported that the heart is both a target of systemic Fgf21 and a local source of Fgf21, and showed that Fgf21 acts as a protective cardiomyokine in the face of insults such as oxidative stress and pathological cardiac events (e.g. cardiac remodeling). 12, 13 In pregnancy, cardiac hypertrophy does not develop as a pathological event but as a normal physiological compensatory response that enables the heart to enhance its pumping capacity in response to increased demand. All measurements are expressed as mean ± SEM. Data were analyzed by two-way ANOVA, where *P < 0.05 for interaction effect, # P < 0.05 for pregnancy effect (n = 5-6/group). LV, left ventricle; LVIDd, LV internal diameter during diastole; LVIDs, LV internal diameter during systole; IVSd, internal ventricular septum during diastole; IVSs, internal ventricular septum during systole; PWTd, posterior wall thickness during diastole; PWTs, posterior wall thickness during systole. EDV, end-diastolic volume; ESV, end-systolic volume; SI, sphericity index. EF, ejection fraction; FS, fractional shortening. Although, some basal signs of cardiac hypertrophy develop spontaneously in the Fgf21-null mice and this is one of the limitations of our study, our observation that pregnancy-induced cardiac remodeling does not further develop in Fgf21-knockout mice suggests that Fgf21 is a key mediator of this physiological adaptation to pregnancy. This hypothesis is supported by the natural pregnancy-related upregulations in the expression and function of Fgf21. The appropriate action of Fgf21 appears to be required for cardiac adaptations to pregnancy, as evidenced by the lack of cardiac hypertrophy, reduced oxidation of fatty acids (major metabolic substrates 21 ), and some signs of fibrosis in the hearts of pregnant Fgf21-null mice. However, we cannot rule out the influence of side variables associated with our experimental model of genetic invalidation.
There is still some debate regarding whether changes in intracellular substrate and metabolite levels in the heart are a cause or consequence of cardiac dysfunction. However, several studies support the idea that altered cardiac metabolism, in the sense of impaired usage of fatty acids and preferential usage of glucose as metabolic fuel is involved in the development of cardiac derangements. 22, [44] [45] [46] A strong increase in cardiac FAO is a known metabolic adaptation to pregnancy, 20 and the impaired induction of FAO in pregnant mice when they lack Fgf21 is consistent with a role for Fgf21 in the regulation of cardiac remodeling in pregnancy. Finally, it cannot be ruled out that impairment in overall mitochondrial oxidative activity due to the lack of Fgf21 affects cardiac metabolism during pregnancy, but to a lower extent. The increases in both circulating and cardiac levels of Fgf21 during pregnancy (a model of physiological cardiac hypertrophy) suggest the involvement of both autocrine and endocrine cardioprotective functions of Fgf21. In pathological hypertrophy, in contrast, the circulating levels of Fgf21 are unchanged and Fgf21 expression is specifically upregulated in the heart, indicating that Fgf21 plays a predominantly autocrine protective role in pathological cardiac pathology. 12, 47 Confirmation of an endocrine/autocrine role of cardiac FGF21 in vivo will require further experimental research based on tissue-specific loss-of-function models. Moreover, a limitation of our study is the use of a rodent model which does not recapitulate exactly the same features of the cardiac human response to gestation, although it has been described a relative eccentric cardiac hypertrophy in human gestation. 48 Furthermore, in the clinical context, the precise distinction between physiological and pathological hypertrophy during pregnancy in humans seems to be not that clear. 49 Further studies are needed in order to clarify the exact role of Fgf21 in cardiac remodeling during human pregnancies. In summary, we herein show that the pregnancy-related systemic and cardiac upregulations of Fgf21 enable the heart to functionally and metabolically adapt to pregnancy. We also establish for the first time that Fgf21 is a relevant component of the molecular machinery that induces physiological cardiac hypertrophy during pregnancy. These findings contribute to our understanding of the molecular mechanisms underlying the physiologically adaptive vs. pathological processes of cardiac hypertrophy, and thus may have important clinical implications in the management of cardiac disease.
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